Table 1.
Characteristics of the 316 Patients with Crohn’s Disease at the Time of Surgery
| Characteristics | Overall population (n = 316) | Anti-TNF naïve patients (n = 117) | Anti-TNF-exposed patients (n = 199) | ||
|---|---|---|---|---|---|
| Age at the time of surgery (yr) | 38.8 ± 14.2 | 40.8 ± 15.4 | 37.7 ± 13.4 | ||
| Disease duration (yr) | 9.0 (2.0–18.0) | 7.0 (0.5–18.0) | 11.0 (5.0–17.0) | ||
| Female sex | 160 (50.6) | 66 (56.4) | 94 (47.2) | ||
| Smokers | 37 (11.7) | 16 (13.7) | 21 (10.5) | ||
| Montreal classification | |||||
| Location | |||||
| L1 | 113 (35.8) | 51 (43.6) | 62 (31.2) | ||
| L2 | 18 (5.7) | 5 (4.3) | 13 (6.5) | ||
| L3 | 185 (58.5) | 61 (52.1) | 124 (62.3) | ||
| L4 | 16 (5.1) | 4 (3.4) | 12 (6.0) | ||
| Perianal lesions | 72 (22.8) | 20 (17.1) | 52 (26.1) | ||
| Behavior | |||||
| B1 | 20 (6.3) | 7 (6.0) | 13 (6.7) | ||
| B2 | 152 (48.1) | 53 (45.3) | 99 (49.7) | ||
| B3 | 144 (45.6) | 57 (48.7) | 87 (43.7) | ||
| Prior intestinal resection | 119 (37.7) | 36 (31.0) | 83 (41.7) | ||
| Medications before surgery | |||||
| Thiopurines | 177 (55.7) | 66 (57.4) | 151 (76.3) | ||
| Methotrexate | 50 (15.8) | 6 (5.1) | 44 (22.1) | ||
| Anti-TNF-naïve | 117 (37.0) | 117 (100) | 0 | ||
| 1 Biologic | 107 (33.9) | 0 | 107 (53.8) | ||
| 2 Biologics | 54 (17.1) | 0 | 54 (27.1) | ||
| 3 Biologics | 25 (7.9) | 0 | 25 (12.6) | ||
| 4 Biologics | 9 (2.8) | 0 | 9 (4.5) | ||
| 5 Biologics | 4 (1.2) | 0 | 4 (2.0) | ||
| Infliximab | 137 (43.3) | 0 | 137 (68.9) | ||
| Adalimumab | 135 (42.7) | 0 | 135 (67.8) | ||
| Certolizumab pegol | 48 (15.2) | 0 | 48 (24.1) | ||
| Vedolizumab | 16 (5.0) | 0 | 16 (8.0) | ||
| Ustekinumab | 4 (1.2) | 0 | 4 (2.0) | ||
| Primary failure to any anti-TNF agents | 96 (30.4) | 0 | 96 (48.2) | ||
| Intestinal resection length (cm) | 22.0 (11.5–35.1) | 29.0 (19.0–43.5) | 36.5 (22.5–54.8) | ||
| Intestinal resection length > 30 cm | 170 (53.8) | 54 (46.2) | 116 (58.3) | ||
| Indication for surgery | |||||
| Failure to medical therapy | 7 (2.2) | 2 (1.7) | 5 (2.5) | ||
| Stricture | 184 (52.8) | 62 (53.0) | 122 (61.3) | ||
| Fistula/abscess | 119 (37.6) | 51 (43.6) | 68 (34.2) | ||
| Cancer/dysplasia | 6 (1.9) | 2 (1.7) | 4 (2.0) | ||
| Medications after surgery | |||||
| No treatment | 41 (13.0) | 27 (23.1) | 14 (7.0) | ||
| 5-ASA | 7 (2.2) | 5 (4.3) | 2 (1.0) | ||
| Thiopurines | 131 (41.0) | 48 (41.0) | 47 (23.6) | ||
| Methotrexate | 41 (15.8) | 6 (5.1) | 35 (17.6) | ||
| Metronidazole | 38 (12.0) | 11 (9.4) | 27 (13.6) | ||
| Anti-TNF agents | 148 (46.8) | 23 (19.7) | 125 (62.8) | ||
| Infliximab | 45 (14.2) | 10 (8.5) | 35 (17.6) | ||
| Adalimumab | 91 (28.8) | 13 (11.0) | 78 (39.2) | ||
| Certolizumab pegol | 10 (3.2) | 0 | 10 (5.0) | ||
| Golimumab | 1 (0.3) | 0 | 1 (0.5) | ||
| Anti-TNF combotherapy | 76 (24.1) | 12 (10.2) | 64 (32.2) | ||
| Vedolizumab | 18 (5.7) | 3 (2.5) | 15 (7.5) | ||
| Ustekinumab | 4 (1.2) | 0 | 4 (2.0) | ||
Values are presented as mean±SD, median (IQR), or number (%).
TNF, tumor necrosis factor; 5-ASA, 5-aminosalicylates; SD, standard deviation; IQR, interquartile range.